Skip to main
OM
OM logo

Outset Medical (OM) Stock Forecast & Price Target

Outset Medical (OM) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Outset Medical Inc has demonstrated strong performance in console sales for Q3, surpassing expectations despite a delay in one major order, which is anticipated to contribute to the company's path to profitability. The company is actively pursuing cost reduction and manufacturing efficiency initiatives while aiming for a gross margin milestone of 50%, supported by an adj. gross margin of 39.8% that exceeds both consensus estimates and prior guidance. Furthermore, the accelerating consumables ordering and the expanding average order size indicate robust market traction for the Tablo system, positioning Outset Medical favorably within the under-penetrated dialysis market.

Bears say

Outset Medical Inc has lowered its full-year revenue guidance by approximately $7 million, reflecting ongoing delays in enterprise deal timing and weaker-than-expected consumables revenue due to reduced orders from acute care customers. The company's total revenues fell to $29.4 million, below both its prior estimates and consensus expectations, primarily due to delayed recognition of console orders and the anticipated slip of major deals into 2026. Additionally, the recent departure of the head of sales may further disrupt sales efforts during a critical period, contributing to a negative outlook for the company's financial performance.

Outset Medical (OM) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Outset Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Outset Medical (OM) Forecast

Analysts have given Outset Medical (OM) a Buy based on their latest research and market trends.

According to 3 analysts, Outset Medical (OM) has a Buy consensus rating as of Dec 8, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Outset Medical (OM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.